Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

bobbseytwins2001

kdd999

To: Karuna1 who wrote (49585)	1/22/2019 1:33:15 PM
From: KeeptheFaith	2 Recommendations of 63311

<<Didn’t Daiichi Sankyo reported results from their study which works similar to IMMU 132? It is getting scarier.>> Per the DS website, they do not list this in late stage development but rather in their pipeline. More specific: DS-1062 (Anti-Trop-2 ADC) is being tested for NSCLC target in Japan and the US. It is in Phase 1. -KTF

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next